Obermatt

Flags

Financial distress

McKesson

NYQ:MCK · US58155Q1031
Health Care Providers & ServicesX-Large

360

83
EV / EBIT53
Price / Owner Earnings61
Owner Earnings Yield89
Dividend Yield81
Price/Sales97
EV / Gross Profit58
Price/Book1
Return on Capital100
Cash Return on Capital100
EBIT Margin15
Gross Profitability35
Cash Conversion19
Accruals24
Owner Earnings Margin28
Sales growth35
Profit Growth94
Long-Term EPS Growth63
Owner Earnings Growth92
Reinvestment43
Price momentum80
Debt load3
Refinancing12
Debt Payback79
Liquidity85
Analyst ratings75
Opinion Changes55
Price Target Upside55
Market mood85
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

McKesson generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
TypePublic Company
ExchangeNYSE
Founded1994
Employees18,502
ISINUS58155Q1031
Last UpdateApr 2, 2026
Themes
Data IntegrationProcess AutomationPharmacovigilanceGeneticsOphthalmologyRheumatologyHealth DiagnosticsPain ManagementVaccinesSoftware DevelopmentOncologyBiopharmaBiotechnologyHealth CareInformation TechnologyPharmaceutical

Description

McKesson Corporation (‘McKesson’), together with its subsidiaries, operates as a diversified healthcare service company. The company’s teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deli…

Analysis

Middle-of-the-road

McKesson Corporation is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is fair. You pay 19.2× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 6% yearly growth; analysts expect 14%. The price, in other words, assumes less than the experts do.

The trajectory is solid and the balance sheet is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
75
2023202420252026

All-time high

100

Dec 2025

All-time low

49

Feb 2026

Average rank

86

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
97
87
91
91
Price/Earnings
33
49
51
86
Price/Book
1
100
100
3
Dividend Yield
81
72
73
67
Value (overall)
63
92
93
92

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare McKesson with its peers
American Well
NYQ:AMWL
36
CountryUSA
IndustryHealth Care Technology
SizeSmall
Full Stock Analysis →
GeneDx
NSQ:WGS
6
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Phreesia
NYQ:PHR
70
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
TruBridge
NSQ:TBRG
50
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
CorVel
NSQ:CRVL
51
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Definitive Healthcare
NSQ:DH
44
CountryUSA
IndustryHealth Care Technology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →